Accéder au contenu
Merck

Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence.

Bioorganic & medicinal chemistry letters (2011-05-03)
Klaus Urbahns, Takeshi Yura, Muneto Mogi, Masaomi Tajimi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki, Timothy B Lowinger, Heinrich Meier, Fiona Chan, David Madge, Jang B Gupta
RÉSUMÉ

We have identified naphthol derivatives as inhibitors of the vanilloid receptor TRPV1 by high throughput screening. The initial lead showed high clearance in rats and has been optimized by enhancing the acidity of the phenol group. Compound 6b has reduced clearance, improved potency and is active in rat cystometry models of urinary incontinence after intravenous administration.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hydroxylamine hydrochloride, 99.999% trace metals basis
Sigma-Aldrich
Hydroxylamine hydrochloride, 99.995% trace metals basis